Published in Cancer Epidemiol Biomarkers Prev on September 01, 2008
Automated breast segmentation of fat and water MR images using dynamic programming. Acad Radiol (2015) 1.65
Magnetic resonance imaging for secondary assessment of breast density in a high-risk cohort. Magn Reson Imaging (2009) 1.56
Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study. Breast Cancer Res (2009) 1.42
Agreement of mammographic measures of volumetric breast density to MRI. PLoS One (2013) 1.35
A new bias field correction method combining N3 and FCM for improved segmentation of breast density on MRI. Med Phys (2011) 1.23
Quantitative analysis of breast parenchymal patterns using 3D fibroglandular tissues segmented based on MRI. Med Phys (2010) 1.05
Impact of skin removal on quantitative measurement of breast density using MRI. Med Phys (2010) 1.04
Automated fibroglandular tissue segmentation and volumetric density estimation in breast MRI using an atlas-aided fuzzy C-means method. Med Phys (2013) 0.99
Comparison of breast density measured on MR images acquired using fat-suppressed versus nonfat-suppressed sequences. Med Phys (2011) 0.99
Age- and race-dependence of the fibroglandular breast density analyzed on 3D MRI. Med Phys (2010) 0.96
Reduction of breast density following tamoxifen treatment evaluated by 3-D MRI: preliminary study. Magn Reson Imaging (2010) 0.94
Normal parenchymal enhancement patterns in women undergoing MR screening of the breast. Eur Radiol (2011) 0.90
Breast density assessment using a 3T MRI system: comparison among different sequences. PLoS One (2014) 0.88
Template-based automatic breast segmentation on MRI by excluding the chest region. Med Phys (2013) 0.88
Comparison of breast tissue measurements using magnetic resonance imaging, digital mammography and a mathematical algorithm. Phys Med Biol (2012) 0.87
Comparative study of density analysis using automated whole breast ultrasound and MRI. Med Phys (2011) 0.86
Segmentation of the breast skin and its influence in the simulation of the breast compression during an X-ray mammography. ScientificWorldJournal (2012) 0.86
Atlas-based probabilistic fibroglandular tissue segmentation in breast MRI. Med Image Comput Comput Assist Interv (2012) 0.84
Computational simulation of breast compression based on segmented breast and fibroglandular tissues on magnetic resonance images. Phys Med Biol (2010) 0.83
Imaging Breast Density: Established and Emerging Modalities. Transl Oncol (2015) 0.82
Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MR. NMR Biomed (2013) 0.81
Consistency of breast density measured from the same women in four different MR scanners. Med Phys (2012) 0.81
Inter- and intra-observer agreement of BI-RADS-based subjective visual estimation of amount of fibroglandular breast tissue with magnetic resonance imaging: comparison to automated quantitative assessment. Eur Radiol (2016) 0.79
The Effect of Change in Body Mass Index on Volumetric Measures of Mammographic Density. Cancer Epidemiol Biomarkers Prev (2015) 0.79
Comparison of Dixon Sequences for Estimation of Percent Breast Fibroglandular Tissue. PLoS One (2016) 0.78
Correlation of endogenous hormonal levels, fibroglandular tissue volume and percent density measured using 3D MRI during one menstrual cycle. Ann Oncol (2013) 0.78
Association between breast cancer, breast density, and body adiposity evaluated by MRI. Eur Radiol (2015) 0.78
A computerized volumetric segmentation method applicable to multi-centre MRI data to support computer-aided breast tissue analysis, density assessment and lesion localization. Med Biol Eng Comput (2016) 0.77
Quantification of Regional Breast Density in Four Quadrants Using 3D MRI-A Pilot Study. Transl Oncol (2015) 0.77
Impact of positional difference on the measurement of breast density using MRI. Med Phys (2015) 0.76
Ultrasound Tomography Evaluation of Breast Density: A Comparison With Noncontrast Magnetic Resonance Imaging. Invest Radiol (2017) 0.75
Double-Blind Randomized 12-Month Soy Intervention Had No Effects on Breast MRI Fibroglandular Tissue Density or Mammographic Density. Cancer Prev Res (Phila) (2015) 0.75
Pre-natal exposures and breast tissue composition: findings from a British pre-birth cohort of young women and a systematic review. Breast Cancer Res (2016) 0.75
Opportunistic Breast Density Assessment in Women Receiving Low-dose Chest Computed Tomography Screening. Acad Radiol (2016) 0.75
Impact of Different Analytic Approaches on the Analysis of the Breast Fibroglandular Tissue Using Diffusion Weighted Imaging. Biomed Res Int (2017) 0.75
Current and Future Methods for Measuring Breast Density: A Brief Comparative Review. Breast Cancer Manag (2015) 0.75
Mammographic density and the risk and detection of breast cancer. N Engl J Med (2007) 14.32
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin (2007) 12.19
Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 10.35
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet (2005) 6.18
Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst (1995) 5.93
The quantitative analysis of mammographic densities. Phys Med Biol (1994) 5.71
A breast cancer prediction model incorporating familial and personal risk factors. Stat Med (2004) 5.30
Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst (2004) 2.87
Fatty and fibroglandular tissue volumes in the breasts of women 20-83 years old: comparison of X-ray mammography and computer-assisted MR imaging. AJR Am J Roentgenol (1997) 2.66
Correlation between mammographic density and volumetric fibroglandular tissue estimated on breast MR images. Med Phys (2004) 2.34
Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res (1997) 2.27
Quantification of breast tissue index from MR data using fuzzy clustering. Conf Proc IEEE Eng Med Biol Soc (2004) 1.93
Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics (1999) 1.77
Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res (2006) 1.77
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging (2000) 1.47
Quantitative correlation of breast tissue parameters using magnetic resonance and X-ray mammography. Br J Cancer (1996) 1.43
Quantitative magnetic resonance imaging parameters and their relationship to mammographic pattern. J Natl Cancer Inst (1992) 0.94
Breast cancer risk and possible screening strategies for young women following supradiaphragmatic irradiation for Hodgkin's disease. Clin Radiol (2004) 0.85
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin (2007) 12.19
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet (2009) 8.30
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet (2006) 7.72
Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet (2010) 7.62
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet (2006) 6.67
Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia (2011) 5.53
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet (2006) 4.23
Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst (2010) 3.94
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst (2011) 3.73
Are current health behavioral change models helpful in guiding prevention of weight gain efforts? Obes Res (2003) 3.62
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat (2014) 3.46
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet (2003) 3.24
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst (2013) 2.93
Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst (2004) 2.87
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol (2013) 2.71
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66
Single reading with computer-aided detection for screening mammography. N Engl J Med (2008) 2.58
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol (2008) 2.56
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ (2012) 2.44
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer (2006) 2.35
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol (2011) 2.14
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
School-based obesity prevention: a blueprint for taming the epidemic. Am J Health Behav (2002) 1.99
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res (2014) 1.97
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol (2012) 1.90
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
Mutations in the gene encoding the Sigma 2 subunit of the adaptor protein 1 complex, AP1S2, cause X-linked mental retardation. Am J Hum Genet (2006) 1.85
Early outcomes of active surveillance for localized prostate cancer. BJU Int (2005) 1.84
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer (2007) 1.84
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst (2006) 1.83
RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet (2011) 1.80
Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed (2002) 1.80
Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet (2011) 1.77
Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res (2006) 1.77
Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet (2012) 1.76
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A (2013) 1.72
Evaluating the effectiveness of using standard mammogram form to predict breast cancer risk: case-control study. Cancer Epidemiol Biomarkers Prev (2008) 1.66
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) (2011) 1.64
Reproducibility of quantitative dynamic MRI of normal human tissues. NMR Biomed (2002) 1.63
IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet (2005) 1.62
Evaluation of Fanconi Anemia genes in familial breast cancer predisposition. Cancer Res (2003) 1.62
Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol (2007) 1.60
Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology (2006) 1.60
Therapeutic target metabolism observed using hyperpolarized 15N choline. J Am Chem Soc (2008) 1.60
Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet (2003) 1.58
Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol (2009) 1.58
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 1.56
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol (2009) 1.52
A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. Hum Mol Genet (2013) 1.52
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2. J Med Genet (2013) 1.51
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinic. Psychooncology (2003) 1.47
Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study. Dev Med Child Neurol (2012) 1.47
Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer (2007) 1.45
Validation of nonrigid image registration using finite-element methods: application to breast MR images. IEEE Trans Med Imaging (2003) 1.43
Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study. Breast Cancer Res (2009) 1.42
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res (2012) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell (2011) 1.40